Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system (CNS) diseases and disorders, today announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million.

The Dandy-Walker Alliance is collaborating with Bionaut Labs to educate our constituency about an investigational new treatment for obstructive hydrocephalus associated with Dandy-Walker Syndrome.

Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors

The U.S. Food and Drug Administration (FDA) has granted the Company humanitarian use device (HUD) designation for BNL-201 for the local treatment of Dandy Walker Syndrome, a rare pediatric neurological disorder.

The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients. BNL-101 is a drug-device combination comprised of doxorubicin as the active drug component together with the company’s Bionaut™ microscale robots.

Announced its launch backed by $20 million financing led by Khosla Ventures. Other investors in the syndicate included Upfront Ventures, Revolution, BOLD Capital, and Compound. Proceeds from the financing support the advancement of the Company’s lead therapeutic program in glioma through preclinical development, as well as help advance its program in Huntington’s disease.